BofA points to the Eli Lilly market that could outsize the U.S.
Bank of America said Eli Lilly’s (LLY) international obesity market could eventually exceed U.S. sales. BofA raised its LLY price target to $1,344 from $1,334 after Q2 results. Lilly reported $23.0B revenue (+48% YoY) and adjusted $8.38/share, and raised FY revenue guidance to $85B-$87B. BofA highlighted oral GLP-1 Foundayo and Medicare GLP-1 Bridge access.
How this was made
The 30-second read
Why it matters
BofA’s raised target is based on an unchanged valuation multiple applied to updated 2027 underlying earnings, plus a thesis that non-U.S. GLP-1 obesity sales could eventually exceed U.S. sales as international markets approach parity and oral access expands addressable demand.
Market read
Traders may adjust LLY positioning as the narrative shifts from U.S. obesity growth concerns to international expansion and oral GLP-1 adoption, supported by a Q2 beat and raised FY guidance.
What to watch
Foundayo’s U.S. debut was modest ($98M vs ~$103M expected), and the international swing factor depends on approvals, uptake, and competitive timing versus Novo’s oral launch.
Background
The article discusses LLY’s Q2 results and how Bank of America reframed the obesity market debate toward international growth and the oral GLP-1 pill Foundayo.
Ticker impact
BofA raised its LLY price target to $1,344 after the company beat Q2 expectations and lifted its full-year revenue forecast to $85B-$87B.
Near-term bias modestly bullish as traders reprice the international growth narrative and the probability-weighted impact of Foundayo’s early-2027 rollout.
The new decision is an analyst target increase tied to specific LLY fundamentals (Q2 beat, FY guide raise) plus a concrete thesis (international GLP-1 nearing parity, Foundayo mix skewing non-U.S.). However, the biggest catalyst (early-2027 approvals/launch impact) is still forward-looking, limiting immediate price impact.
Market effects
Reinforces the GLP-1 obesity growth debate moving toward ex-U.S. penetration and oral formulations, which can influence sentiment across large pharma obesity franchises.
Highlights Europe, Japan, and China as key growth vectors where Mounjaro demand is accelerating and where oral options may unlock additional patients.
Supports a global re-rating narrative for obesity drug demand as international markets approach U.S. GLP-1 sales parity.
Counterpoint
If U.S. pricing continues to fall faster than volume growth, the international upside thesis may not offset near-term margin and earnings sensitivity.
Key entities
- companyEli Lilly
Subject of the article, with Q2 results, raised full-year revenue forecast, and an oral GLP-1 pill (Foundayo) positioned as a key international catalyst.
- financial_institutionBank of America
Issued a Global Research report lifting its LLY price objective and emphasizing international obesity market growth.
- productFoundayo
Lilly’s oral GLP-1 pill, expected to roll out overseas in early 2027, with BofA estimating a majority of peak sales outside the U.S.
- policyMedicare GLP-1 Bridge program
Launched July 1, expanding coverage to about 20 million eligible beneficiaries and supporting U.S. demand.
